A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

Cancer

Volumn 112, Issue 3, 2008, Pages 521-526

  Ross, Robert W ^a   Beer, Tomasz M ^b   Jacobus, Susanna ^a   Bubley, Glenn J ^c   Taplin, Mary Ellen ^a   Ryan, Christopher W ^b   Huang, Jiaoti ^d   Oh, William K ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Carboplatin; Chromogranin A; Docetaxel refractory; Prostate cancer

Indexed keywords

CARBOPLATIN; CHROMOGRANIN A; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; THROMBOSIS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHROMOGRANIN A; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 38749141779     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23195     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
4. Oh W, Tay M, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone refractory prostate cancer? Cancer. 2007;109:477-486.
5. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003;98:2592-2598.
6. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44-53.
7. Cabrespine A, Guy L, Gachon F, Cure H, Chollet P, Bay JO. Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol. 2006;175:1347-1352.
8. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. The use of the calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol. 1995;121:478-486.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
10. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
11. Kaplan EL, Meier R. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
12. Cox D. Analysis of binary data. London, United Kingdom: Methuen and Company; 1970.
13. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (s) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol. 2007;25(18 suppl):5019.
14. Canobbio L, Guarneri D, Miglietta L, Decensi A, Oneto F, Boccardo F. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer. 1993;29A:2094-2096.
15. Jungi WF, Bernhard J, Hurny C, et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer.Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer. 1998;6:462-468.
16. Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res. 1995;15:2825-2828.
17. Trump DL, Marsh JC, Kvols LK, et al. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs. 1990;8(suppl 1):S91-S94.
18. Castagneto B, Ferraris V, Perachino M, et al. Weekly administration of standardized low-dose carboplatin (CBDCA) in the treatment of advanced hormone refractory prostate cancer (HRPC): a phase II study. Presented at the American Society of Clinical Oncology 2006 Prostate Cancer Symposium, San Francisco, California, February 24-26, 2006. Abstract 243.
19. Rosenberg JE, Weinberg VK, Kelly WK, et al. Randomized phase II study of ixabepilone or mitoxantrone (lx) and prednisone (MP) in patients with taxane resistant (TR) hormone refractory prostate cancer (HRPC) Presented at the American Society of Clinical Oncology 2006 Prostate Cancer Symposium, San Francisco, California, February 24-26, 2006. Abstract 253.
20. Michaelson MD, Gilligan T, Oh W, et al. Phase II study of three-hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). ASCO Meeting Abstracts. 2005;23:4517.